Lung :: Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN? in patients with various sarcomas that have metastasized to the lung.